BGI Group participated in the comprehensive and large-scale genome project launched in Abu Dhabi, UAE.

BGI Genomics successfully developed the SARS-CoV-2 nucleic acid testing kits and donated over 130,000 kits in China.

BGI Genomics SARS-CoV-2 testing kit and the MGI DNBSEQ-T7 sequencing system obtained the emergency approval from China National Medical Product Administration and became the first batch of COVID-19 testing products approved for the market.

Since the beginning of operation in Wuhan, BGI Genomics has built “Huo-Yan” Laboratories in multiple Chinese cities including Shenzhen, Tianjin and Beijing to effectively assist local pandemic prevention and control efforts. Meanwhile, “Huo-Yan” Laboratories were built in countries including Serbia,...

BGI-Research cooperated with the teams from Germany, Denmark and Belgium to discover a new phylum “prasinodermophyta”. This is the first discovery made by Chinese scientists in the category “phylum”.

Mathias UHLEN

“The quality of the data produced in the project (based on MGI’s DNBSEQ sequencing platform) is very satisfactory. In fact, this is the best data we have ever seen.”